NASDAQ:HSKAHeska Stock Price, Forecast & News

$86.70

-0.30 (-0.34 %)

(As of 05/28/2020 02:57 PM ET)

Add

Compare

Today's Range

$85.13

Now: $86.70▼

$88.98

50-Day Range

$56.00

MA: $70.29▼

$82.45

52-Week Range

$50.00

Now: $86.70▼

$110.90

Volume5,221 shs

Average Volume58,565 shs

Market Capitalization$814.11 million

P/E RatioN/A

Dividend YieldN/A

Beta1.68

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. The company's Other Vaccines and Pharmaceuticals segment offers a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. Heska Corporation sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.

Beat the Market (BTM) Rank^™

1.2 Analyst's Opinion

Consensus Rating
Heska has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $81.80, Heska has a potential downside of 5.7% from its current price of $86.70.
Amount of Analyst Coverage
Heska has only been the subject of 2 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Heska has received 319 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Heska has received 357 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Heska has received 52.81% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Heska and other stocks. Vote “Outperform” if you believe HSKA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HSKA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Heska does not currently pay a dividend.
Dividend Growth
Heska does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Heska insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $147,390.00 in company stock.
Percentage Held by Insiders
Only 11.70% of the stock of Heska is held by insiders.
Percentage Held by Institutions
79.78% of the stock of Heska is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Heska are expected to grow in the coming year, from ($0.44) to $0.27 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Heska is -86.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Heska is -86.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Heska has a P/B Ratio of 3.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.04 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Diagnostic substances

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:HSKA

Previous Symbol

CUSIPN/A

CIK1038133

Webwww.heska.com

Phone970-493-7272

Debt

Debt-to-Equity Ratio0.19

Current Ratio11.21

Quick Ratio9.89

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$122.66 million

Price / Sales6.64

Cash Flow$0.99 per share

Price / Cash Flow87.62

Book Value$28.82 per share

Price / Book3.01

Profitability

EPS (Most Recent Fiscal Year)$0.05

Net Income$-1,470,000.00

Net Margins-5.99%

Return on Equity-1.04%

Return on Assets-0.75%

Miscellaneous

Employees347

Outstanding Shares9,390,000

Market Cap$814.11 million

Next Earnings Date8/4/2020 (Estimated)

OptionableNot Optionable

Receive HSKA News and Ratings via Email

Sign-up to receive the latest news and ratings for HSKA and its competitors with MarketBeat's FREE daily newsletter.

Heska (NASDAQ:HSKA) Frequently Asked Questions

How has Heska's stock been impacted by COVID-19 (Coronavirus)?

Heska's stock was trading at $81.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HSKA shares have increased by 6.0% and is now trading at $86.70. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Heska?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heska in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Heska.

When is Heska's next earnings date?

Heska is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Heska.

How were Heska's earnings last quarter?

Heska Corp (NASDAQ:HSKA) released its quarterly earnings data on Thursday, May, 7th. The medical research company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.44. The medical research company had revenue of $30.65 million for the quarter, compared to analysts' expectations of $33.47 million. Heska had a negative net margin of 5.99% and a negative return on equity of 1.04%. View Heska's earnings history.

What guidance has Heska issued on next quarter's earnings?

Heska updated its FY 2020 Pre-Market earnings guidance on Thursday, May, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $175-185 million, compared to the consensus revenue estimate of $150.44 million.

What price target have analysts set for HSKA?

6 equities research analysts have issued 1-year target prices for Heska's shares. Their forecasts range from $59.00 to $105.00. On average, they expect Heska's share price to reach $81.80 in the next year. This suggests that the stock has a possible downside of 5.7%. View analysts' price targets for Heska.

What are Wall Street analysts saying about Heska stock?

Here are some recent quotes from research analysts about Heska stock:

1. According to Zacks Investment Research, "Heska Corporation sells advanced veterinary diagnostic and specialty products. Heska's state-of-the-art offerings include blood testing instruments and supplies, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The Company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled support to veterinarians. " (5/9/2020)
2. Canaccord Genuity analysts commented, "We view this financing as overdue" as the company had been operating for some time at a cash balance hovering around $10 million. We trim our out year revenue and earnings estimates as we exercise more conservatism on Heska’s top line growth, and we expect a higher level of spending to help return the company to growth, following ~3 years of missing expectations. We are cautiously optimistic to see Heska deliver on its growth initiatives, however, our near-term expectations are tempered until we see evidence of stronger commercial execution. While we trim our estimates and price target to $75 (from $95), we are sticking with our BUY rating in hopes we see progress on new product and geographic expansion as we look out to 2020. Convertible notes." (9/12/2019)

Has Heska been receiving favorable news coverage?

Press coverage about HSKA stock has trended very negative on Thursday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Heska earned a daily sentiment score of -3.8 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutHeska.

Are investors shorting Heska?

Heska saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 578,600 shares, a drop of 21.0% from the April 15th total of 732,600 shares. Based on an average daily volume of 75,600 shares, the short-interest ratio is presently 7.7 days. Approximately 8.1% of the company's stock are short sold. View Heska's Current Options Chain.

Who are some of Heska's key competitors?

Some companies that are related to Heska include Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Quotient (QTNT), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Vermillion (VRML), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB), ImmuCell (ICCC), GeneNews (GNWSF), Akers Biosciences (AKER) and Achieve Life Sciences (ACHV). View all competitors.

What other stocks do shareholders of Heska own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Netflix (NFLX), NVIDIA (NVDA), Shopify (SHOP), Adobe (ADBE), Exxon Mobil (XOM), AbbVie (ABBV), Skyworks Solutions (SWKS), Alibaba Group (BABA) and Biogen (BIIB).

Who are Heska's key executives?

Heska's management team includes the following people:

Mr. Kevin S. Wilson, CEO, Pres & Director (Age 47)
Mr. Jason A. Napolitano, COO & Chief Strategist (Age 51)
Ms. Catherine I. Grassman CPA, VP, Chief Accounting Officer & Corp. Controller (Age 43)
Dr. Nancy Wisnewski, Exec. VP of Diagnostic Operations & Product Devel. (Age 56)
Mr. Jason D. Aroesty, Exec. VP of International Diagnostics (Age 44)

What is Heska's stock symbol?

Heska trades on the NASDAQ under the ticker symbol "HSKA."

Who are Heska's major shareholders?

Heska's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (14.07%), Fred Alger Management LLC (11.49%), Nine Ten Capital Management LLC (3.61%), Riverbridge Partners LLC (3.69%), State Street Corp (3.66%) and Ranger Investment Management L.P. (2.38%). Company insiders that own Heska stock include Bonnie J Trowbridge, G Irwin Gordon, Jason A Napolitano, Kevin S Wilson, Nancy Wisnewski, Rod Lippincott, Scott Humphrey, Steve Asakowicz and Steven M Eyl. View institutional ownership trends for Heska.

Which institutional investors are selling Heska stock?

HSKA stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., BlackRock Inc., Public Sector Pension Investment Board, WINTON GROUP Ltd, Morgan Stanley, Aviva PLC, Bank of New York Mellon Corp, and New York State Common Retirement Fund. View insider buying and selling activity for Heska.

Which institutional investors are buying Heska stock?

HSKA stock was bought by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, Grandeur Peak Global Advisors LLC, JPMorgan Chase & Co., Fred Alger Management LLC, Russell Investments Group Ltd., Motley Fool Asset Management LLC, Engineers Gate Manager LP, and Nine Ten Capital Management LLC. View insider buying and selling activity for Heska.

How do I buy shares of Heska?

Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Heska's stock price today?

One share of HSKA stock can currently be purchased for approximately $86.70.

How big of a company is Heska?

Heska has a market capitalization of $814.11 million and generates $122.66 million in revenue each year. The medical research company earns $-1,470,000.00 in net income (profit) each year or $0.05 on an earnings per share basis. Heska employs 347 workers across the globe.

What is Heska's official website?

The official website for Heska is www.heska.com.

How can I contact Heska?

Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company can be reached via phone at 970-493-7272 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff